Unknown

Dataset Information

0

BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.


ABSTRACT: The AKT/PKB pathway plays a central role in tumor development and progression and is often up-regulated in different tumor types, including melanomas. We have recently reported on the in silico approach to identify putative inhibitors for AKT/PKB. Of the reported hits, we selected BI-69A11, a compound which was shown to inhibit AKT activity in in vitro kinase assays. Analysis of BI-69A11 was performed in melanoma cells, a tumor type that commonly exhibits up-regulation of AKT. Treatment of the UACC903 human melanoma cells, harboring the PTEN mutation, with BI-69A11 caused efficient inhibition of AKT S473 phosphorylation with concomitant inhibition of AKT phosphorylation of PRAS40. Treatment of melanoma cells with BI-69A11 also reduced AKT protein expression, which coincided with inhibition of AKT association with HSP-90. BI-69A11 treatment not only caused cell death of melanoma, but also prostate tumor cell lines. Notably, the effect of BI-69A11 on cell death was more pronounced in cells that express an active form of AKT. Significantly, intra-peritoneal injection of BI-69A11 caused effective regression of melanoma tumor xenografts, which coincided with elevated levels of cell death. These findings identify BI-69A11 as a potent inhibitor of AKT that is capable of eliciting effective regression of xenograft melanoma tumors.

SUBMITTER: Gaitonde S 

PROVIDER: S-EPMC2860277 | biostudies-literature | 2009 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.

Gaitonde Supriya S   De Surya K SK   Tcherpakov Marianna M   Dewing Antimone A   Yuan Hongbin H   Riel-Mehan Megan M   Krajewski Stan S   Robertson Gavin G   Pellecchia Maurizio M   Ronai Ze'ev Z  

Pigment cell & melanoma research 20090117 2


The AKT/PKB pathway plays a central role in tumor development and progression and is often up-regulated in different tumor types, including melanomas. We have recently reported on the in silico approach to identify putative inhibitors for AKT/PKB. Of the reported hits, we selected BI-69A11, a compound which was shown to inhibit AKT activity in in vitro kinase assays. Analysis of BI-69A11 was performed in melanoma cells, a tumor type that commonly exhibits up-regulation of AKT. Treatment of the U  ...[more]

Similar Datasets

| S-EPMC3158838 | biostudies-literature
| S-EPMC4912424 | biostudies-literature
| S-EPMC5790369 | biostudies-literature
| S-EPMC2820291 | biostudies-literature
| S-EPMC4466678 | biostudies-literature
| S-EPMC5171235 | biostudies-literature
| S-EPMC10382964 | biostudies-literature
| S-EPMC7472885 | biostudies-literature
| S-EPMC10742282 | biostudies-literature
| S-EPMC2866129 | biostudies-literature